Cantor Fitzgerald Reiterates Overweight on Zevra Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Zevra Therapeutics (NASDAQ:ZVRA).
October 11, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Zevra Therapeutics, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst suggests confidence in the stock's potential performance, likely leading to positive investor sentiment and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100